Multimodal Nuclear Factor-Erythroid-2-Related Factor (NRF2) Therapy in the Context of Mammalian Target of Rapamycin (mTOR) Inhibition Reprograms the Acute Systemic and Pulmonary Immune Response after Combined Burn and Inhalation Injury

Matthew D Alves; Ryan A Clark; Denise A Hernandez; Madelyn P Bucci; Duo Chen; Philip A Efron; Shannon M Wallet; Ben G Keselowsky; Robert Maile

doi:10.1097/SHK.0000000000002466

Multimodal Nuclear Factor-Erythroid-2-Related Factor (NRF2) Therapy in the Context of Mammalian Target of Rapamycin (mTOR) Inhibition Reprograms the Acute Systemic and Pulmonary Immune Response after Combined Burn and Inhalation Injury

Shock. 2024 Aug 21. doi: 10.1097/SHK.0000000000002466. Online ahead of print.

Authors

Matthew D Alves¹, Ryan A Clark², Denise A Hernandez¹, Madelyn P Bucci³, Duo Chen¹, Philip A Efron¹, Shannon M Wallet³, Ben G Keselowsky², Robert Maile

Affiliations

¹ Sepsis and Critical Illness Research Center, Department of Surgery, University of Florida, Gainesville, FL, USA.
² J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
³ Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, 32611, USA.

PMID: 39178221
DOI: 10.1097/SHK.0000000000002466

Abstract

Severe burn injuries induce acute and chronic susceptibility to infections, which is largely attributed to a hyper-pro-inflammatory response followed by a chronic anti-inflammatory response. Concurrent inhalation injury (B + I) causes airway inflammation. Pulmonary macrophages and neutrophils are "hyperactive" with increased reactive oxygen (ROS) and nitrogen species (RONS) activity, but are unable to clear infection, causing airway damage upon activation. Nuclear Factor-Erythroid-2-Related Factor (NRF2) is a critical immunomodulatory component that induces compensatory anti-inflammatory pathways when activated. On the other hand, inhibition of Mammalian Target of Rapamycin (mTOR) reduces pro-inflammatory responses. The therapeutic use of these targets is limited, as known modulators of these pathways are insoluble in saline and require long-term administration. A biocompatible NRF2 agonist (CDDO) and rapamycin (RAPA) poly (lactic-co-glycolic acid) (PLGA) microparticles (MP) were created, which we hypothesized would reduce the acute hyper-inflammatory response in our murine model of B + I injury. BI-injured mice that received CDDO-MP or both CDDO-MP and RAPA-MP (Combo-MP) an hour after injury displayed significant changes in the activation patterns of pulmonary and systemic immune genes and their associated immune pathways 48 h after injury. For example, mice treated with Combo-MP showed a significant reduction in inflammatory gene expression compared to untreated or CDDO-MP-treated mice. We also hypothesized that Combo-MP therapy would acutely decrease bacterial susceptibility after injury. BI-injured mice that received Combo-MP an hour after injury, inoculated 48 h later with Pseudomonas aeruginosa (PAO1), and sacrificed 48 h after infection, displayed significantly decreased bacterial counts in the lungs and liver versus untreated B + I mice. This reduction in infection was accompanied by significantly altered lung and plasma cytokine profiles and immune reprogramming of pulmonary and splenic cells. Our findings strongly suggest that multimodal MP-based therapy holds considerable promise for reprogramming the immune response after burn injuries, particularly by mitigating the hyper-inflammatory phase, and preventing subsequent susceptibility to infection.